KangLaiTe USA (KangLaiTe) is a privately held biotechnology company that develops treatments for solid tumor cancers and for cancer-associated anorexia-cachexia syndrome (CACS). Its main product is kanglaite injection, used for the treatment of patients with advanced non-small cell lung cancer (NSCLC) and hepatocellular cancer. This Injection is a sterile microemulsion for intravenous administration. KangLaiTe collaborates with researchers at Johns Hopkins University to find the efficacy and mechanism of action of the product in animal and in vitro models. The technology of kanglaite injection was originally developed in China and focuses on the symptoms of the patients first. The company is a wholly owned subsidiary of Zhejiang Kanglaite Group Company. KangLaiTe is headquartered at Alameda in California, the US.